SOHO 2021 | The importance of optimizing treatment of B-ALL at induction
Rachel Rau
• 31 Aug 2021
Rachel Rau, MD, of Baylor College of Medicine, Houston, TX, suggests how treatment can be optimized at induction to achieve the best possible outcomes for patients with B-cell acute lymphoblastic leukemia (B-ALL), and explains the importance of optimizing treatment early. Dr Rau also explains that patients in the relapsed/refractory setting who don’t respond to chemotherapy may benefit from an earlier introduction of bispecific T-cell engagers (BiTEs) such as blinatumomab. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Disclosures
Rachel Rau, MD, has participated in consultancy work with Jazz and Servier.
